List view / Grid view
22 January 2016 | By Victoria White
The FDA has approved the supplemental New Drug Application (sNDA) of Amgen’s Kyprolis (carfilzomib) for injection in combination with dexamethasone or with lenalidomide plus dexamethasone...
22 January 2016 | By Victoria White
NICE recommends that nivolumab is made available on the NHS as a treatment option for patients with advanced (unresectable or metastatic) melanoma...
21 January 2016 | By Victoria White
In the Phase III trials, significantly more patients treated with Viberzi experienced improvements in diarrhoea and abdominal pain, as compared with placebo...
21 January 2016 | By Victoria White
The pulmonary arterial hypertension treatment market will grow from $3.45 billion in 2014 to $4.75 billion by 2024, according to research and consulting firm GlobalData...
21 January 2016 | By Victoria White
Vasopharm has designed a Phase III registration study in Europe of VAS203 in in moderate to severe traumatic brain injury...
21 January 2016 | By Victoria White
More than 80 companies and organisations have signed the Declaration on Combating Antimicrobial Resistance (AMR), an industry-wide call to action...
21 January 2016 | By Sartorius Stedim Biotech
The ideal solution for scaling studies and low volume ultra- and diafiltration operations...
20 January 2016 | By Victoria White
Venetoclax is an investigational small molecule designed to selectively bind and inhibit the BCL-2 protein, which plays an important role in a process called apoptosis...
20 January 2016 | By Victoria White
Gavi has provided US$ 5 million towards the development of Merck’s rVSV∆G-ZEBOV-GP live attenuated Ebola Zaire vaccine, on the understanding that it will be submitted for licensure by the end of 2017...
20 January 2016 | By Victoria White
GlobalData says the expansion will be slight due to the patent expiration of all existing branded drugs in the chronic hepatitis B therapeutics space during the forecast period, and continued low diagnosis and treatment rates of the disease...
20 January 2016 | By Black Swan Analysis
Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases...
20 January 2016 | By Victoria White
Immunocore has announced the start of the Phase Ib/II combination trial evaluating IMCgp100 with durvalumab and tremelimumab for the treatment of metastatic cutaneous melanoma...
Lilly and Incyte have announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis (RA).
19 January 2016 | By Victoria White
With this authorisation, Oncaspar will provide an important treatment option for more European patients with this rapidly progressing cancer of the white blood cells...
19 January 2016 | By Victoria White
In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease...
